VEFORA.- Randomized multicenter phase II/III study evaluating efficacy and tolerance (composite criterion) of chemotherapy with fractionated cisplatine/gemcitabine or carboplatine/gemcitabine in advanced or metastatic urothelial cancer patients with impaired renal function (creatinine clearance between 40 and 60 ml/min according to Cockroft and Gault).

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-5424 Call for proposal: PHRC12

Funded under: PHRC

VEFORA.- Randomized multicenter phase II/III study evaluating efficacy and tolerance (composite criterion) of chemotherapy with fractionated cisplatine/gemcitabine or carboplatine/gemcitabine in advanced or metastatic urothelial cancer patients with impaired renal function (creatinine clearance between 40 and 60 ml/min according to Cockroft and Gault).

- Summary
- DMPs

Partners

Institut Bergonié , ICM-VAL D'AURELLE , Institut Gustave Roussy , Centre Léon Bérard , Hôpital Jean Minjoz , Centre Hospitalier de Mont-de-Marsan , Centre Hospitalier Universitaire de Nîmes , Institut de cancérologie Lucien Neuwirth , Centre François Baclesse , CHV , Centre René Gauducheau , Centre Georges-François Leclerc , Institut de Cancérologie de l'Ouest , Institut Claudius Regaud , Hôpital Saint-Louis

Data Management Plans

Start a new DMP in Argos

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::291c287ab5ed936e2a1d8c1944661167&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Loading